ВЕСТОН Кристофер,КЛАРИДЖ Ли Чарльз,АДАМС Дэвид,СМИТ Дэвид,ВЕСТЕРЛУНД Нина,ПИХЛАВИСТО Марьо,ЭСТЕРМАН Туа
申请号：
RU2012113561
公开号：
RU2012113561A
申请日:
2010.09.07
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. The VAP-1 inhibitor, which is: i) a fully human anti-VAP-1 antibody containing one to three consensus CDR sequences selected from the group consisting of sequences of SEQ ID NO: 1-3, and / or a polypeptide a light chain containing one to three consensus CDR sequences selected from the group consisting of sequences of SEQ ID NO: 24-26； or ii) an SSAO inhibitor selected from hydrazine derivatives, derivatives of 4,5,6,7-tetrahydroimidazo [4,5-c] pyridine, thiocarbamoyl derivatives, carboxamides, sulfonamides, thiazole and / or guanidine derivatives, oxime derivatives, dihydrazine, arylalkylamines, oxazolidinones, haloalkylamines, derivatives of benfotiamine and imidazopyridine for use as an antifibrotic agent. 2. The VAP-1 inhibitor according to claim 1, wherein said anti-VAP-1 antibody comprises a heavy chain polypeptide comprising a first CDR sequence selected from SEQ ID NO: 4-8, a second CDR sequence selected from SEQ ID NO: 9-13, and a third CDR sequence selected from the sequences of SEQ ID NO: 14-18, and / or a light chain polypeptide containing the first CDR sequence selected from the sequences of SEQ ID NO: 27-31, the second CDR- a sequence selected from the sequences of SEQ ID NO: 32-36, and a third CDR sequence, selected nnuyu sequences of SEQ ID NO: 37-41.3. The VAP-1 inhibitor according to claim 2, wherein said anti-VAP-1 antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 19-23 and the corresponding light chain variable region, containing amino acid sequence�1. Ингибитор VAP-1, который представляет:i) полностью человеческое анти-VAP-1-антитело, содержащее одну-три консенсусных CDR-последовательности, выбранных из группы, состоящей из последовательностей SEQ ID NO: 1-3, и/или полипептид легкой цепи, содержащий одну-три консенсусных CDR-последовательности, выбранных из группы, состоящей из последовательностей SEQ ID NO: 24-26； илиii) ингибитор SSAO, выбранный из производных
